Why are the First-Line Therapies Used as Injections Discontinued in the Treatment of Multiple Sclerosis?
International Archives of Medical Research · 2022
DOI: 10.56484/iamr.1087921 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Archives of Medical Research, 2022. Verfasst von Sedat ŞEN und 1 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Yok.
Abstract (Originalsprache)
Objective
Immunomodulatory therapies (IMTs) are used in the treatment of multiple sclerosis (MS) considering their efficacy and safety. Although other effective treatments have been used in recent years, the use of IMTs still continues. In this study, we aimed to reveal the reasons for the discontinuation of IMTs used as injections.
Method
IMTs data of 1464 patients were collected and analysed from the Imed database, where 20-year data of the patients were entered by us. Groups were divided as; Interferon beta-1a subcutaneous (IFN-β1a SC), Interferon beta-1a intramuscular (IFN-β1a IM), glatiramer acetate (GA) and Interferon beta-1b (IFN-β1b). Age, gender, duration of illness, types of disease onset, time to start the injection, duration of injection therapy, and reason for discontinuation of patients were analysed.
Results
The most common reason for discontinuation of treatments was found to be disease progression (20.13%, 28.14%, 19.64%, 23.87%). Side effects, increased attack frequency, patient demand, disease activity detection in imaging methods, and pregnancy planning followed the disease progression respectively.
Conclusion
IMTs as an injection form are used in the treatment of MS, considering their effectiveness and reliability. The most common reason for discontinuing treatment is disease progression.
Förderung
- Yok
Zitieren
APA
ŞEN, S., & TERZİ, M. (2022). Why are the First-Line Therapies Used as Injections Discontinued in the Treatment of Multiple Sclerosis?. International Archives of Medical Research. https://doi.org/10.56484/iamr.1087921
Vancouver
ŞEN S, TERZİ M. Why are the First-Line Therapies Used as Injections Discontinued in the Treatment of Multiple Sclerosis?. International Archives of Medical Research. 2022. doi:10.56484/iamr.1087921
BibTeX
@article{EN2022,
author = {ŞEN, Sedat and TERZİ, Murat},
title = {Why are the First-Line Therapies Used as Injections Discontinued in the Treatment of Multiple Sclerosis?},
journal = {International Archives of Medical Research},
year = {2022},
doi = {10.56484/iamr.1087921}
}
EUVIMED